In the next five years, new therapeutic approaches will drive the market for
autoimmune disorder treatments to grow at a rate of over 15%, to a value of over
$21 billion by 2006. The third largest category of illness in the industrialized
world—behind heart disease and cancer—autoimmune disease is now the
focus of increased research funding, leading to the development of highly
successful products.
And Theta' s new study, Autoimmune Disease Therapeutics Worldwide: Markets
& Developments will answer your key market and R&D questions:
- What new treatments have already reached market? Are in development?
- What are the current and projected market sizes and shares for the
treatments for each of these disorders?
- Which companies are developing new treatments? When will they reach the
market? Will they be commerically successful?
- How is recent legislation and funding impacting R&D for these
disorders?
Autoimmune Disease Therapeutics Worldwide covers the range of disorders,
including:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Inflammatory bowel disease
- Psoriasis
- Multiple sclerosis
- Thyroid disease
- Sjogren' s syndrome
- Myasthenia gravis.
Illustrated with detailed tables and full-color charts, Autoimmune Disease
Therapeutics Worldwide cuts through the mass of raw data and gives you the
value-added analysis to make the right decisions in this highly competitive
market. Order your copy today!
View Cart
